Company profile: Adnexus Therapeutics
1.1 - Company Overview
Company description
- Provider of discovery and development of Adnectins, a novel proprietary class of targeted biologics designed to block or stimulate therapeutic targets to fight diseases across a broad range of therapeutic areas; operates as a Bristol-Myers Squibb R&D company in the United States.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Adnexus Therapeutics
Veru
HQ: United States
Website
- Description: Provider of novel medicines and healthcare products, including enobosarm to prevent muscle loss in patients using GLP-1 drugs and to treat metastatic breast cancer; sabizabulin for hospitalized patients with viral-induced ARDS; and the FDA-approved FC2 Female Condom for prevention of pregnancy and sexually transmitted infections, available by prescription.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veru company profile →
Novo Nordisk
HQ: Denmark
Website
- Description: Provider of insulin and other diabetes drugs for chronic diseases, GLP-1 treatments for type 2 diabetes, obesity care pharmaceuticals, Mim8 for haemophilia A (weekly or monthly dosing), and ReMed, a recycling program for used injection pens, with a focus on pioneering scientific breakthroughs and expanding access to medicines to prevent and cure disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novo Nordisk company profile →
Saniona
HQ: Denmark
Website
- Description: Provider of pharmaceutical research and development focused on advancing multiple potential new medicines through clinical trials and pioneering highly selective ion channel modulators, leveraging a well-established approach to disease treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Saniona company profile →
NeRRe Therapeutics
HQ: United Kingdom
Website
- Description: Provider of biotechnology R&D focused on clinical and pre-clinical neurokinin receptor antagonists, including Orvepitant, a neurokinin-1 receptor antagonist in development for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF). Founded in 2012 and based in Stevenage, United Kingdom.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeRRe Therapeutics company profile →
Merck
HQ: Germany
Website
- Description: Provider of life science, healthcare, and electronics solutions in the U.S. and Canada as EMD Serono, MilliporeSigma, and EMD Electronics. Supplies lab chemicals, solvents, materials, and tools; process solutions for drug development; end-to-end testing, analytics, and manufacturing support; develops medicines and devices for cancer, multiple sclerosis, fertility, and endocrine disorders; and materials/equipment for semiconductors, displays, and surfaces.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Merck company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Adnexus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Adnexus Therapeutics
2.2 - Growth funds investing in similar companies to Adnexus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Adnexus Therapeutics
4.2 - Public trading comparable groups for Adnexus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →